As concerns about bacterial resistance to antibiotics grow, researchers are racing to find new kinds of drugs to replace ones that are no longer effective. One promising new class of molecules called acyldepsipeptides—ADEPs—kills bacteria in a way that no marketed antibacterial drug does—by altering the pathway through which cells rid themselves of harmful proteins.
Now, researchers from Brown Univ. and the Massachusetts Institute of Technology have shown that giving the ADEPs more backbone can dramatically increase their biological potency. By modifying the structure of the ADEPs in ways that make them more rigid, the team prepared new ADEP analogs that are up to 1,200 times more potent than the naturally occurring molecule.
A paper describing the research was released online by the Journal of the American Chemical Society.
“The work is significant because we have outlined and validated a strategy for the enhancing the potency of this promising class of antibacterial drug…
View original post 788 more words